Searchable abstracts of presentations at key conferences in endocrinology

ea0032p902 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Efficacy and safety of lanreotide in combination with cabergoline in clinical practice in patients with active acromegaly with monotherapy failure

Vilchez Ricardo , Bernabeu Ignacio , Blanco Concepcion , Cordido Fernando , Paja Miguel , Casany Rosa , Fajardo Carmen , Maraver Silvia , Martin Tomas , Lucas Tomas , Arnes Juan Antonio Garcia , Catalina Pablo Fernandez , Icaya Maria Purificacion Martinez de , Sesmilo Gemma , Pico Antonio , Marazuela Monica , Soto Alfonso , Domingo Manuel Puig , on behalf of ACROCOMB study group

Introduction: ACROCOMB, a retrospective Spanish Multicenter study, evaluated the efficacy and safety of lanreotide (LAN) combined with cabergoline (CAB), or pegvisomant in patients with acromegaly.Methods: patients treated with LAN+CAB at 44 Spanish Endocrinology Departments were included.Results: 33% male patients, median age: 50.4 years. Mean time from diagnosis: 5.9±6.9 years. Tumour size at diagnosis: 21.9 mm. 83% of patie...